BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20400238)

  • 1. Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Aydogan B; Liang Y; Yeginer M; Hasselle MD; Dandekar V; Bafana R; Yashar CM; Mundt AJ; Roeske JC; Mell LK
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):800-7. PubMed ID: 20400238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations Between Radiation Dose in Bone Marrow and Hematological Toxicity in Patients With Cervical Cancer: A Comparison of 3DCRT, IMRT, and RapidARC.
    Chang Y; Yang ZY; Li GL; Li Q; Yang Q; Fan JQ; Zhao YC; Song YQ; Wu G
    Int J Gynecol Cancer; 2016 May; 26(4):770-6. PubMed ID: 26844613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.
    Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U
    Med Oncol; 2016 Jul; 33(7):72. PubMed ID: 27277756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.
    Klopp AH; Moughan J; Portelance L; Miller BE; Salehpour MR; Hildebrandt E; Nuanjing J; D'Souza D; Souhami L; Small W; Gaur R; Jhingran A
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):83-90. PubMed ID: 23582248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between bone marrow dosimetric parameters and acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy: comparison of three-dimensional conformal radiotherapy and intensity-modulated radiation therapy.
    Hui B; Zhang Y; Shi F; Wang J; Wang T; Wang J; Yuan W; Li Y; Liu Z
    Int J Gynecol Cancer; 2014 Nov; 24(9):1648-52. PubMed ID: 25275663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data.
    Liang Y; Messer K; Rose BS; Lewis JH; Jiang SB; Yashar CM; Mundt AJ; Mell LK
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):912-9. PubMed ID: 20472344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
    Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
    Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
    Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
    Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
    Wan J; Liu K; Li K; Li G; Zhang Z
    Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
    Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT.
    Albuquerque K; Giangreco D; Morrison C; Siddiqui M; Sinacore J; Potkul R; Roeske J
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1043-7. PubMed ID: 20471182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
    Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
    Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
    Huang J; Gu F; Ji T; Zhao J; Li G
    Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review.
    Corbeau A; Kuipers SC; de Boer SM; Horeweg N; Hoogeman MS; Godart J; Nout RA
    Radiother Oncol; 2021 Nov; 164():128-137. PubMed ID: 34560187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.